Development of vaccines for chikungunya fever

Journal of Infectious Diseases

Volumn 214, Issue , 2016, Pages S488-S496

  Erasmus, Jesse H ^a,b,c   Rossi, Shannan L ^a,b,c   Weaver, Scott C ^a,b,c  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b Institute for Translational Science   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alphavirus; Arthralgia; Chikungunya; Vaccine

Indexed keywords

CHIKUNGUNYA VACCINE; DNA VACCINE; INACTIVATED VACCINE; LIVE VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE; VIRUS VECTOR; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

CHIKUNGUNYA; CHIKUNGUNYA VIRUS; CONFERENCE PAPER; DRUG CONTROL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; HUMAN; INFECTION PREVENTION; INVESTMENT; LICENSING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; SEROCONVERSION; SIDE EFFECT; VACCINE IMMUNOGENICITY; VACCINE PRODUCTION; VIRUS INACTIVATION; VIRUS REPLICATION; ANIMAL; ARTHRALGIA; BLOOD; CHIKUNGUNYA FEVER; CLINICAL TRIAL (TOPIC); EPIDEMICS; IMMUNOLOGY; STANDARDS; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ARTHRALGIA; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; CLINICAL TRIALS AS TOPIC; EPIDEMICS; HUMANS; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 85015843720     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw271     Document Type: Conference Paper

References (61)

1. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquitoborne disease. N Engl J Med 2015; 372:1231-9.
2. Simon F, Javelle E, Cabie A, et al. French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Med Mal Infect 2015; 45:243-63.
3. Akahata W, Yang ZY, Andersen H, et al. Avirus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16:334-8.
4. Apandi Y, Nazni WA, Noor Azleen ZA, et al. The first isolation of chikungunya virus from nonhuman primates in Malaysia. J Gen Mol Virol 2009; 1:35-9.
5. Number of reported cases of chikungunya fever in the Americas, by country or territory 2015 (to week noted) cumulative cases epidemiological week / EW52. http://www. paho. org/hq/index. php?option=com-docman&task=doc- view&Itemid=270&gid=33091&lang=en. Accessed 19 July 2016.
6. Volk SM, Chen R, Tsetsarkin KA, et al. Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J Virol 2010; 84:6497-504.
7. Tsetsarkin KA, Chen R, Yun R, et al. Multi-peaked adaptive landscape for chikungunya virus evolution predicts continued fitness optimization in Aedes albopictus mosquitoes. Nat Commun 2014; 5:4084.
8. Nitatpattana N, Kanjanopas K, Yoksan S, et al. Long-term persistence of chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand. Virol J 2014; 11:183.
9. Labadie K, Larcher T, Joubert C, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 2010; 120:894-906.
10. Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE, Lupton HW. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 1986; 4:157-62.
11. Gardner J, Anraku I, Le TT, et al. Chikungunya virus arthritis in adult wild-type mice. J Virol 2010; 84:8021-32.
12. Nakaya HI, Gardner J, Poo YS, Major L, Pulendran B, Suhrbier A. Gene profiling of chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis Rheum 2012; 64:3553-63.
13. Poo YS, Rudd PA, Gardner J, et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl Trop Dis 2014; 8:e3354.
14. Couderc T, Khandoudi N, Grandadam M, et al. Prophylaxis and therapy for chikungunya virus infection. J Infect Dis 2009; 200:516-23.
15. Morrison TE, Oko L, Montgomery SA, et al. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol 2011; 178:32-40.
16. Sun S, Xiang Y, Akahata W, et al. Structural analyses at pseudo atomic resolution of chikungunya virus and antibodies show mechanisms of neutralization. Elife 2013; 2:e00435.
17. Couderc T, Chretien F, Schilte C, et al. A mouse model for chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 2008; 4:e29.
18. Partidos CD, Weger J, Brewoo J, et al. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine 2011; 29:3067-73.
19. Yoon IK, Alera MT, Lago CB, et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl Trop Dis 2015; 9:e0003764.
20. Kam YW, Lee WW, Simarmata D, et al. Longitudinal analysis of the human antibody response to chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol 2012; 86:13005-15.
21. Chu H, Das SC, Fuchs JF, et al. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against chikungunya in the A129 mouse model. Vaccine 2013; 31:3353-60.
22. Plante K, Wang E, Partidos CD, et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog 2011; 7:e1002142.
23. Franklin RP, Kinde H, Jay MT, et al. Eastern equine encephalomyelitis virus infection in a horse from California. Emerg Infect Dis 2002; 8:283-8.
24. Harrison VR, Eckels KH, Bartelloni PJ, Hampton C. Production and evaluation of a formalin-killed chikungunya vaccine. J Immunol 1971; 107:643-7.
25. Capeding MR, Chua MN, Hadinegoro SR, et al. Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children. PLoS Negl Trop Dis 2013; 7:e2331.
26. Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of chikungunya virus. Vaccine 2009; 27:2513-22.
27. Khan M, Dhanwani R, Rao PV, Parida M. Subunit vaccine formulations based on recombinant envelope proteins of chikungunya virus elicit balanced Th1/ Th2 response and virus-neutralizing antibodies in mice. Virus Res 2012; 167:236-46.
28. Kumar M, Sudeep AB, Arankalle VA. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 2012; 30:6142-9.
29. Weber C, Buchner SM, Schnierle BS. A small antigenic determinant of the chikungunya virus E2 protein is sufficient to induce neutralizing antibodies, which are partially protective in mice. PLoS Negl Trop Dis 2015; 9:e0003684.
30. Metz SW, Martina BE, van den Doel P, et al. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 2013; 31:6092-6.
31. Metz SW, Gardner J, Geertsema C, et al. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 2013; 7:e2124.
32. Chang LJ, Dowd KA, Mendoza FH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014; doi:10. 1016/S0140-6736(14)61185-5.
33. DeZure AD, Berkowitz NM, Graham BS, Ledgerwood JE. Whole-inactivated and virus-like particle vaccine strategies for chikungunya virus. J Infect Dis 2016; 214(suppl 5):S497-9.
34. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000; 62:681-5.
35. Gorchakov R, Wang E, Leal G, et al. Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the e2 envelope glycoprotein. J Virol 2012; 86:6084-96.
36. Wang E, Volkova E, Adams AP, et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008; 26:5030-9.
37. Wang E, Kim DY, Weaver SC, Frolov I. Chimeric chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response. J Virol 2011; 85:9249-52.
38. Finkelstein Y, Faktor O, Elroy-Stein O, Levi BZ. The use of bi-cistronic transfer vectors for the baculovirus expression system. J Biotechnol 1999; 75:33-44.
39. Roy CJ, Adams AP,Wang E, et al. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis 2014; 209:1891-9.
40. Partidos CD, Paykel J, Weger J, et al. Cross-protective immunity against o'nyongnyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine 2012; 30:4638-43.
41. Ramsauer K, Tangy F. Chikungunya virus vaccines: viral vector based approaches. J Infect Dis 2016; 214(suppl 5):S500-5.
42. Brandler S, Ruffie C, Combredet C, et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 2013; 31:3718-25.
43. Ramsauer K, Schwameis M, Firbas C, et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 2015.
44. Chattopadhyay A, Wang E, Seymour R, Weaver SC, Rose JK. A chimeric vesiculo/ alphavirus is an effective alphavirus vaccine. J Virol 2013; 87:395-402.
45. Gomez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines 2013; 12:1395-416.
46. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004; 15:1022-33.
47. Garcia-Arriaza J, Cepeda V, Hallengard D, et al. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol 2014; 88:3527-47.
48. Wang D, Suhrbier A, Penn-Nicholson A, et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 2011; 29:2803-9.
49. Barouch DH, Pau MG, Custers JH, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172:6290-7.
50. Gudmundsdotter L, Nilsson C, Brave A, et al. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009; 27:4468-74.
51. Nasar F, Gorchakov RV, Tesh RB, Weaver SC. Eilat virus host range restriction is present at multiple levels of the virus life cycle. J Virol 2015; 89:1404-18.
52. Mallilankaraman K, Shedlock DJ, Bao H, et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011; 5:e928.
53. Tretyakova I, Hearn J, Wang E, Weaver S, Pushko P. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis 2014; 209:1882-90.
54. Hallengard D, Lum FM, Kummerer BM, et al. Prime-boost immunization strategies against chikungunya virus. J Virol 2014; 88:13333-43.
55. Powers AM, Brault AC, Tesh RB, Weaver SC. Re-emergence of chikungunya and o'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J Gen Virol 2000; 81:471-9.
56. Tan JJ, Capozzoli M, Sato M, et al. An integrated lab-on-chip for rapid identification and simultaneous differentiation of tropical pathogens. PLoS Negl Trop Dis 2014; 8:e3043.
57. Goh LY, Kam YW, Metz SW, et al. A sensitive epitope-blocking ELISA for the detection of chikungunya virus-specific antibodies in patients. J Virol Methods 2015; 222:55-61.
58. Erasmus JH, Needham J, Raychaudhuri S, et al. Utilization of an Eilat virus-based chimera for serological detection of chikungunya infection. PLoS Negl Trop Dis 2015; 9:e0004119.
59. White A, Berman S, Lowenthal JP. Comparative immunogenicities of chikungunya vaccines propagated in monkey kidney monolayers and chick embryo suspension cultures. Appl Microbiol 1972; 23:951-2.
60. Plante KS, Rossi SL, Bergren NA, Seymour RL, Weaver SC. Extended preclinical safety, efficacy and stability testing of a live-attenuated chikungunya vaccine candidate. PLoS Negl Trop Dis 2015; 9:e0004007.
61. Hallengard D, Kakoulidou M, Lulla A, et al. Novel attenuated chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. Journal of virology 2014; 88:2858-66.